USPSTF Issues Draft Recommendation for CRC Screening
TUESDAY, Oct. 27, 2020 -- The U.S. Preventive Services Task Force (USPSTF) concludes that there is a substantial net benefit for screening adults age 50 to 75 years for colorectal cancer (CRC) and moderate net benefit for adults ages 45 to 49 years. These findings form the basis of a draft recommendation statement published online Oct. 27 by the USPSTF.
Jennifer S. Lin, M.D., from the Kaiser Permanente Center for Health Research in Portland, Oregon, and colleagues updated a prior systematic review to support the USPSTF in updating its recommendation on screening for CRC. The researchers found evidence that the guaiac fecal occult blood test performed every year reduces CRC mortality; screening with a fecal immunochemical test performed every year reduces CRC mortality; colonoscopy every 10 years reduces CRC mortality; and flexible sigmoidoscopy every five years reduces CRC mortality.
Based on these findings, the USPSTF recommends screening for CRC in all adults ages 50 to 75 years (Grade A recommendation), which can provide substantial benefit in reducing CRC mortality and increasing life-years gained. For adults ages 45 to 49 years, screening provides a moderate benefit (Grade B recommendation). For adults ages 76 to 85 years, clinicians should selectively offer screening; patients and clinicians should consider overall health and prior screening history to determine whether this screening is appropriate (Grade C recommendation).
The draft recommendation statement and evidence review have been posted for public comment. Comments can be submitted from Oct. 27 to Nov. 23, 2020.
© 2020 HealthDay. All rights reserved.
Posted: October 2020
Read this next
MONDAY, Nov. 23, 2020 -- Social needs are associated with lower health-related quality of life (HRQOL) among African American cancer survivors, according to a study published...
TUESDAY, Nov. 17, 2020 -- For patients with metastatic colorectal cancer who have resectable liver metastases, survival outcomes at five years do not differ significantly for...
MONDAY, Nov. 9, 2020 -- For the most common cancers, cancer drug approvals between 2000 and 2016 were associated with a reduction in deaths, according to a study published online...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.